MICHAEL KLEIN PhD
CONSULTANT
CSSS Services
Product Development
Plan Assessment
Identify a strategic pathway for the study and evaluation of a drug's abuse potential to support regulatory requirements and marketing approval
Report Review and Interpretation
Review nonclinical and clinical study reports, including interpretation of results, for controlled substances and drugs with abuse potential
Preparation of NDA Submissions
Prepare and review NDA submissions to support drug scheduling proposals related to abuse potential and dependence liability studies
Schedule I Substance Studies
Prepare and advise on regulatory submissions related to conducting research on Schedule I substances
Keep Up with New Advances
Maintain currency with the Agency's public viewpoint and guidance to position clients' new products for successful outcome
Protocol Design and
Development
Advise on the design and development of nonclinical
and clinical protocols for the study of abuse potential and dependence liability, and abuse deterrence products
IND Submission and Consultation
Consult on Pre-IND submissions and regulatory meetings, INDs, and product development of drugs with abuse potential
Product Study and Data Evaluation
Collaborate with client's product development team to help manage study consistent with FDA guidelines and evaluate data
Regulatory Outcome Advice
Advise on possible regulatory outcomes for new drug products with abuse potential, including product labeling, drug scheduling, and the need for additional measures
